The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review
Abstract
Recent findings suggest that the cellular and extracellular materials surrounding the cancerous cells from an atypical tumor microenvironment (TM) play a pivotal role in the process of tumor initiation and progression. TM comprises an intricate system involving diverse cell types including endothelial cells, pericytes, smooth muscle cells, fibroblasts, various inflammatory cells, dendritic cells, and cancer stem cells (CSCs). The TM-forming cells dynamically interact with the cancerous cells through various signaling mechanisms and pathways. The existence of this dynamic cellular communication is responsible for creating an environment suitable for sustaining a reasonably high cellular proliferation. Presently, researchers are showing interest to use these TM conditions to mediate effective targeting measures for cancer therapy. The use of nanotherapeutics-based combination therapy; stimuli-responsive nanotherapeutics targeting acidic pH, hypoxic environment; and nanoparticle-induced hyperthermia are some of the approaches that are under intense investigation for cancer therapy. This review discusses TM and its role in cancer progression and crosstalk understanding, opportunities, and epigenetic modifications involved therein to materialize the capability of nanotherapeutics to target cancer by availing TM. STATEMENT OF SIGNIFICANCE: This article presents various recent reports, proof-of-concept studies, patents, and clinical trials on the concept of tumor microenvironment for mediating the cancer-specific delivery of nanotechnology-based systems bearing anticancer drug and diagnostics. We highlight the potential of tumor microenvironment; its role in disease progression, opportunities, challenges, and allied treatment strategies for effective cancer therapy by conceptual understanding of tumor microenvironment and epigenetic modifications involved. Specifically, nanoparticle-based approaches to target various processes related to tumor microenvironment (pH responsive, hypoxic environment responsive, targeting of specific cells involved in tumor microenvironment, etc.) are dealt in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,517
Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,477
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
Acidic extracellular microenvironment and cancer
Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-89 · Cited by 1,300
O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,136
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., Ji, B., Evans, D. B., & Logsdon, C. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5714 · Cited by 1,099
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
The tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Kim, J., Cho, H. R., Jeon, H., Kim, D., Song, C., Lee, N., Choi, S. H., & Hyeon, T. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05559 · Cited by 707
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
Pathophysiology : The Biologic Basis for Disease in Adults and Children
McCance, K. L., & Huether, S. E. (1990) · Medical Entomology and Zoology · Cited by 632
Therapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
Lee, H.-Y., Li, Z., Chen, K., Hsu, A. R., Xu, C., Xie, J., Sun, S., & Chen, X. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051243 · Cited by 557
Li, H.-J., Du, J.-Z., Liu, J., Du, X.-J., Shen, S., Zhu, Y.-H., Wang, X., Ye, X., Nie, S., & Wang, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b02326 · Cited by 537
Ling, D., Park, W., Park, S.-J., Lu, Y., Kim, K. S., Hackett, M. J., Kim, B. H., Yim, H., Jeon, Y. S., Na, K., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4108287 · Cited by 517
History of Cancer, Ancient and Modern Treatment Methods
Sudhakar, A. (2009) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.100000e2 · Cited by 504
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Magnetic nanoparticle drug delivery systems for targeting tumor
Mody, V. V., Cox, A., Shah, S., Singh, A., Bevins, W., & Parihar, H. (2014) · Applied Nanoscience · doi:10.1007/s13204-013-0216-y · Cited by 497
Targeted nanoparticles for cancer therapy
Gu, F. X., Karnik, R., Wang, A. Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., Langer, R. S., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 478
Dendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Self-citationNanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449
Recent Advances in Cancer Therapy: An Overview
Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Vinals, F., & Capella, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941847 · Cited by 446
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
Schrag, D., Weiser, M. R., Goodman, K. A., Gon̈en, M., Hollywood, E., Cercek, A., Reidy-Lagunes, D. L., Gollub, M. J., Shia, J., Guillem, J. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7904 · Cited by 414
Targeted Nanoparticles for Cancer Therapy
Reddy, G. S. N. (2021) · Journal of Bioanalysis & Biomedicine · Cited by 401
Stimuli-responsive nanoparticles for targeting the tumor microenvironment
Du, J., Lane, L. A., & Nie, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.050 · Cited by 382
Winter, P. M., Caruthers, S. D., Kassner, A., Harris, T. D., Chinen, L. K., Allen, J. S., Lacy, E. K., Zhang, H., Robertson, J. D., Wickline, S. A., et al. (2003) · PubMed · Cited by 371
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
Albrengues, J., Bertero, T., Grasset, E., Bonan, S., Maiel, M., Bourget, I., Philippe, C., Herraiz Serrano, C., Benamar, S., Croce, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms10204 · Cited by 367
Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery
Thambi, T., Deepagan, V. G., Yoon, H. Y., Han, H. S., Kim, S.-H., Son, S., Jo, D.-G., Ahn, C.-H., Suh, Y. D., Kim, K., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.022 · Cited by 359
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 339
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S. A., Gladkov, O. A., Holcombe, R. F., Korn, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 333
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Yu, M., Jambhrunkar, S., Thorn, P., Chen, J., Gu, W., & Yu, C. (2013) · Nanoscale · doi:10.1039/c2nr32145a · Cited by 316
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
Daldrup-Link, H. E., Golovko, D., Ruffell, B., DeNardo, D. G., Castaneda, R., Ansari, C., Rao, J., Tikhomirov, G. A., Wendland, M. F., Corot, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3420 · Cited by 300
Rao, W., Wang, H., Han, J., Zhao, S., Dumbleton, J., Agarwal, P., Zhang, W., Zhao, G., Yu, J., Zynger, D. L., et al. (2015) · ACS Nano · doi:10.1021/nn506928p · Cited by 281
Cancer metabolism: The Warburg effect today
Ferreira, L. M. R. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.08.006 · Cited by 281
Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
Lamm, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/314064 · Cited by 264
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.
Bharali, D. J., Khalil, M., Gurbuz, M., et al. (2009) · PubMed · Cited by 238
Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611406113 · Cited by 234
Zhu, S., Niu, M., O’Mary, H., & Cui, Z. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400216r · Cited by 232
HELLMANN, K. (1968) · Nature · doi:10.1038/220308a0 · Cited by 222
Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment
Martínez-Carmona, M., Lozano, D., Colilla, M., & Vallet-Regí, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.007 · Cited by 220
Zhang, Y.-X., Zhao, Y.-Y., Shen, J., Sun, X., Liu, Y., Liu, H., Wang, Y., & Wang, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04296 · Cited by 220
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
Jo, S. D., Ku, S. H., Won, Y.-Y., Kim, S. H., & Kwon, I. C. (2016) · Theranostics · doi:10.7150/thno.15335 · Cited by 218
Liu, Y., Qiao, L., Zhang, S., Wan, G., Chen, B., Zhou, P., Zhang, N., & Wang, Y. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.010 · Cited by 218
Ji, T., Zhao, Y., Ding, Y., Wang, J., Zhao, R., Lang, J., Qin, H., Liu, X., Shi, J., Tao, N., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506262 · Cited by 215
Epigenetic alterations involved in cancer stem cell reprogramming
Muñoz, P., Iliou, M. S., & Esteller, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.006 · Cited by 200
Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., Wang, X., Ke, L., & Shi, K. (2019) · Theranostics · doi:10.7150/thno.29431 · Cited by 199
Zhang, Y., Zhang, H., Wang, X., Wang, J., Zhang, X., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.072 · Cited by 194
Meng, F., Zhong, Y., Cheng, R., Deng, C., & Zhong, Z. (2014) · Nanomedicine · doi:10.2217/nnm.13.212 · Cited by 188
Shen, S., Li, H.-J., Chen, K.-G., Wang, Y.-C., Yang, X.-Z., Lian, Z.-X., Du, J.-Z., & Wang, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01193 · Cited by 186
Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go
Buchsbaum, R., & Oh, S. (2016) · Cancers · doi:10.3390/cancers8020019 · Cited by 183
Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics
Tekade, R. K., Dutta, T., Gajbhiye, V., & Jain, N. K. (2009) · Journal of Microencapsulation · doi:10.1080/02652040802312572 · Cited by 181
Self-citationDreaden, E. C., Morton, S. W., Shopsowitz, K. E., Choi, J.-H., Deng, Z. J., Cho, N.-J., & Hammond, P. T. (2014) · ACS Nano · doi:10.1021/nn502861t · Cited by 179
Nasab, N. A., Kumleh, H. H., Beygzadeh, M., Teimourian, S., & Kazemzad, M. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1290648 · Cited by 177
Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds
Sun, T.-M., Wang, Y.-C., Wang, F., Du, J.-Z., Mao, C.-Q., Sun, C.-Y., Tang, R.-Z., Liu, Y., Zhu, J., Zhu, Y.-H., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.011 · Cited by 174
Ruan, S., He, Q., & Gao, H. (2015) · Nanoscale · doi:10.1039/c5nr01408e · Cited by 173
Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast
Bauer, M., Su, G., Casper, C., He, R., Rehrauer, W., & Friedl, A. (2010) · Oncogene · doi:10.1038/onc.2009.463 · Cited by 172
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 172
Wikberg, M. L., Edin, S., Lundberg, I. V., Van Guelpen, B., Dahlin, A. M., Rutegård, J., Stenling, R., Öberg, Å., & Palmqvist, R. (2013) · Tumor Biology · doi:10.1007/s13277-012-0638-2 · Cited by 171
Semenza, G. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9058-y · Cited by 169
Choi, K. Y., Jeon, E. J., Yoon, H. Y., Lee, B. S., Na, J. H., Min, K. H., Kim, S. Y., Myung, S.-J., Lee, S., Chen, X., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.029 · Cited by 169
Siriwon, N., Kim, Y. J., Siegler, E., Chen, X., Rohrs, J. A., Liu, Y., & Wang, P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0502 · Cited by 169
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity
Albini, A., Bruno, A., Gallo, C., Pajardi, G., Noonan, D. M., & Dallaglio, K. (2015) · Connective Tissue Research · doi:10.3109/03008207.2015.1066780 · Cited by 166
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers
Mousa, S., Bharali, D., Khalil, M., Gurbuz, M., & Simone (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4241 · Cited by 162
Tumor microenvironment for cancer stem cells
Kise, K., Kinugasa‐Katayama, Y., & Takakura, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.08.005 · Cited by 159
Conde, J., Tian, F., Hernández, Y., Bao, C., Cui, D., Janssen, K., Ibarra, M. R., Baptista, P. V., Stoeger, T., & de la Fuente, J. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.041 · Cited by 154
Tumor Microenvironment: A New Treatment Target for Cancer
Tsai, M., Chang, W., Huang, M., & Kuo, P. (2014) · ISRN Biochemistry · doi:10.1155/2014/351959 · Cited by 148
Ernsting, M. J., Hoang, B., Lohse, I., Undzys, E., Cao, P. M., Do, T., Gill, B., Pintilie, M., Hedley, D. W., & Li, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.023 · Cited by 133
Chen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 133
Targeted, Triggered Drug Delivery to Tumor and Biofilm Microenvironments
Benoit, D. S. W., & Koo, H. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0014 · Cited by 126
Tumor targeting and microenvironment-responsive nanoparticles for gene delivery
Huang, S., Shao, K., Kuang, Y., Liu, Y., Li, J., An, S., Guo, Y., Ma, H., He, X., & Jiang, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.043 · Cited by 123
Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia
Abbasi, A. Z., Gordijo, C. R., Amini, M. A., Maeda, A., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3475 · Cited by 121
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 119
Yang, G., Tian, J. H., Chen, C., Jiang, D., Xue, Y., Wang, C., Gao, Y., & Zhang, W. (2019) · Chemical Science · doi:10.1039/c9sc00985j · Cited by 118
Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach
Adjei, I. M., & Sharma, B. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6010081 · Cited by 117
Tekade, R. K., Dutta, T., Tyagi, A., Bharti, A. C., Das, B. C., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802473154 · Cited by 115
Self-citationZhang, J., Miao, L., Guo, S., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.016 · Cited by 110
The energy blocker inside the power house: mitochondria targeted delivery of 3-bromopyruvate
Marrache, S., & Dhar, S. (2014) · Chemical Science · doi:10.1039/c4sc01963f · Cited by 110
Targeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
Chouaı̈b, S., Kiéda, C., Benlalam, H., Noman, M. Z., Mami‐Chouaib, F., & Rüegg, C. (2010) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v30.i6.30 · Cited by 108
Tumor microenvironment and nanotherapeutics.
Upreti, M., Jyoti, A., & Sethi, P. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.08.11 · Cited by 107
Cancer-Associated Fibroblasts as Targets for Immunotherapy
Kakarla, S., Song, X., & Gottschalk, S. M. (2012) · Immunotherapy · doi:10.2217/imt.12.112 · Cited by 106
RNAi-combined nano-chemotherapeutics to tackle resistant tumors
Tekade, R. K., Tekade, M., Kesharwani, P., & D’Emanuele, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.029 · Cited by 106
Self-citationMarra, M., Salzano, G., Leonetti, C., Tassone, P., Scarsella, M., Zappavigna, S., Calimeri, T., Franco, R., Liguori, G., Cigliana, G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.004 · Cited by 104
Shahin, S. A., Wang, R., Simargi, S. I., Contreras, A., Parra, L. E., Qu, L., Wen, W. X., Dellinger, T. H., Unternaehrer, J., Tamanoi, F., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.04.008 · Cited by 99
Ma, M., Chen, H., Chen, Y., Zhang, K., Wang, X., Cui, X., & Shi, J. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm15489g · Cited by 93
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Tran, T. Q., Lowman, X. H., & Kong, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2506 · Cited by 93
Velma, V., Dasari, S. R., & Tchounwou, P. B. (2016) · Biomarker Insights · doi:10.4137/bmi.s39445 · Cited by 92
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
Salzano, G., Marra, M., Porru, M., Zappavigna, S., Abbruzzese, A., Rotonda, M. I. L., Leonetti, C., Caraglia, M., & Rosa, G. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.046 · Cited by 89
Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells
Venturelli, L., Nappini, S., Bulfoni, M., Gianfranceschi, G., Zilio, S. D., Coceano, G., Ben, F. D., Turetta, M., Scoles, G., Vaccari, L., et al. (2016) · Scientific Reports · doi:10.1038/srep21629 · Cited by 87
Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models
HogenEsch, H., & Nikitin, A. Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.031 · Cited by 82
Liu, J.-Y., Chiang, T., Liu, C.-H., Chern, G.-G., Lin, T.-T., Gao, D.-Y., & Chen, Y. (2015) · Molecular Therapy · doi:10.1038/mt.2015.147 · Cited by 80
The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis
Sukowati, C. H. C., Anfuso, B., Crocè, L. S., & Tiribelli, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1196-y · Cited by 79
Babaei, M., Abnous, K., Taghdisi, S. M., Farzad, S. A., Peivandi, M. T., Ramezani, M., & Alibolandi, M. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0028 · Cited by 79
Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer
Niu, M., Valdes, S. A., Naguib, Y. W., Hursting, S. D., & Cui, Z. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00987 · Cited by 78
Fu, S., Xu, Luo, Li, Zhou, Pang, B., Qiu-shi, R., Fu, S., & Cui, D. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28314 · Cited by 77
Tekade, R. K., & Chougule, M. B. (2013) · BioMed Research International · doi:10.1155/2013/712678 · Cited by 77
Self-citationpH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery
Zhu, H., Zhang, S., Ling, Y., Meng, G., Yang, Y. M., & Zhang, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.017 · Cited by 77
Wu, Y., Gu, W., Li, J., Chen, C., & Xu, Z. P. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0237 · Cited by 76
Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery
Son, S., Rao, N. V., Ko, H., Shin, S., Jeon, J., Han, H. S., Nguyen, V. Q., Thambi, T., Suh, Y. D., & Park, J. H. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.11.048 · Cited by 75
Chen, F., Zeng, Y., Qi, X., Chen, Y., Ge, Z., Jiang, Z., Zhang, X., Dong, Y., Chen, H., & Yu, Z. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.015 · Cited by 75
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
Ordikhani, F., Uehara, M., Kasinath, V., Dai, L., Eskandari, S. K., Bahmani, B., Yonar, M., Azzi, J. R., Haik, Y., Sage, P. T., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122700 · Cited by 72
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
Parcesepe, P., Giordano, G., Laudanna, C., Febbraro, A., & Pancione, M. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6261721 · Cited by 71
Modifying the tumor microenvironment using nanoparticle therapeutics
Roy, A., & Li, S. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1406 · Cited by 71
Phillips, K., Jenkins, M. A., Lindeman, G. J., McLachlan, S., McKinley, J. M., Weideman, P. C., Hopper, J. L., Friedlander, M., & kConFab Investigators (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00665.x · Cited by 67
Siegler, E. L., Kim, Y. J., & Wang, P. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.08.002 · Cited by 65
Othman, B. A., Greenwood, C., Abuelela, A. F., Bharath, A. A., Chen, S., Theodorou, I. G., Douglas, T., Uchida, M., Ryan, M. P., Merzaban, J. S., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201501012 · Cited by 60
Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy
Dewaraja, Y. K., Schipper, M. J., Shen, J., Smith, L. B., Murgić, J., Savas, H., Youssef, E., Regan, D. D., Wilderman, S. J., Roberson, P. L., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136044 · Cited by 59
Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse
Church, S., & Galon, J. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.004 · Cited by 57
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases
Talekar, M., Tran, T.-H., & Amiji, M. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9772-2 · Cited by 56
Potential role of immunotherapy in advanced non-small-cell lung cancer
de Mello, R. A., Veloso, A. F. D. H., Catarina, P. E. M., Nadine, S., & Αντωνίου, Γ. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s90459 · Cited by 56
Ikeda, Y., Hisano, H., Nishikawa, Y., & Nagasaki, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00011 · Cited by 52
Sphingosine-1-phosphate and estrogen signaling in breast cancer
Maczis, M. A., Milstien, S., & Spiegel, S. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.09.006 · Cited by 49
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
Quiroga, D. M., Lyerly, H. K., & Morse, M. A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0414-4 · Cited by 46
Niu, L., Xu, K., & Mu, F. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814329668_0021 · Cited by 42
Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors
Hamm, C. A., Stevens, J. W., Xie, H., Vanin, E. F., Morcuende, J. A., Abdulkawy, H., Seftor, E. A., Sredni, S. T., Bischof, J. M., Wang, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-471 · Cited by 37
Poveda, A. M., Pousa, A. L., Martín‐Broto, J., del Muro, J. G., Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M., Escudero, P., et al. (2005) · Sarcoma · doi:10.1080/13577140500287024 · Cited by 37
Thakkar, S., Sharma, D., & Misra, M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.10.008 · Cited by 35
Self-citationYen, J. S., Ying, H., Wang, H., Yin, L., Uckun, F. M., & Cheng, J. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00393 · Cited by 33
Ji, T., Zhao, Y., Ding, Y., Wang, J., Zhao, R., Lang, J., Qin, H., Liu, X., Shi, J. Y., Tao, N., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201506262 · Cited by 27
Valter, K., Chen, L., Kruspig, B., Maximchik, P. V., Cui, H., Zhivotovsky, B., & Gogvadze, V. G. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.016 · Cited by 24
Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells
Chen, B., Liu, P., Zhang, H., Wu, X., Guo, L., Wang, F., Xia, G., Yin, H., Wang, Y., & Li, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s108169 · Cited by 23
New approaches to treat cancer - what they can and cannot do.
Utku, N. (2011) · PubMed · Cited by 13
Obermair, A., Youlden, D. R., Baade, P. D., & Janda, M. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12508 · Cited by 7
Cited by
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Strategies for enhancing cancer chemodynamic therapy performance
Jana, D., & Zhao, Y. (2022) · Exploration · doi:10.1002/exp.20210238 · Cited by 284
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy
Fu, S., Li, G., Zang, W., Zhou, X., Shi, K., & Zhai, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.012 · Cited by 266
Deep learning in digital pathology for personalized treatment plans of cancer patients
Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.02.003 · Cited by 34
Metadata
- Authors
- Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K.
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 101
- Pages
- 43-68
- ISSN
- 1742-7061 (ISSN-L)
- OpenAlex
- W2972802464
- Cited by
- 316
- References
- 155
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.